Niagen Bioscience, Inc. (NAGE) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Ladies and gentlemen, thank you for standing by and welcome to Niagen Bioscience Inc.' 's first quarter 2026 earnings conference call. My name is Karina and I will be the conference operator today. At this time, all participants are in a listen-only mode. As a reminder, this conference call is being recorded. Earlier today, Niagen Bioscience issued a press release announcing its financial results for the first quarter of 2026. If you have not reviewed this information... It is available within the Investor Relations section of Niogen Bioscience's website at www.niogenbioscience.com. I would now like to turn the call over to Lauren Brzozanski, Assistant Controller. Please go ahead. Good afternoon, and welcome to Niogen Bioscience, Inc.' 's first quarter 2026 conference call. Joining me today are our Chief Executive Officer, Rob Freed, Chief Financial Officer, Ozan Pamir, and Senior Vice President of Scientific and Regulatory Affairs, Dr. Andrew Hsiao. Dr. Hsiao will be joining the call for Q&A. Before we begin, I'd like to remind everyone that today's call may include forward-looking statements. These statements relate to, among other things, our research and development activities, clinical trial plans and timing, regulatory filings, expansion into new markets, business development opportunities, and our expected financial and operating performance. These statements are based on our current expectations as of today and are subject to risks and uncertainties that could cause actual results to differ materially. For a discussion of these risks, please refer to our most recent forum time queue and other filings with the SEC. We undertake no obligation to update these statements except as required by law. In addition, we may reference certain non-GAAP financial measures....